IRB Approval

Minimal Risk IRB (Health Sciences)
1/21/2021
Submission ID number:
Title:
Principal Investigator:
Point-of-contact:
IRB Staff Reviewer:

2013-1357-CR008
ORegon CHild Absenteeism due to Respiratory Disease Study
Jonathan L Temte
Shari K Barlow
Jessica Johnson

A designated MR IRB member conducted an expedited review of the above-referenced
continuing review progress report form. The study was approved by the IRB member for the
period of 12 months with the expiration date of 1/20/2022. The study qualified for expedited
review pursuant to 45 CFR 46.110 and, if applicable, 21 CFR 56.110 and 38 CFR 16.110:
Category 9: The study meets ALL of the following criteria: (i) Categories 2 through 8 do not
apply; (ii) The research is not conducted under an investigational new drug application or
investigational device exemption; AND (iii) The IRB has determined and documented at a
convened meeting that the research involves no greater than minimal risk and no additional risks
have been identified
To access the materials approved by the IRB, including any stamped consent forms and
recruitment materials, please log in to your ARROW account and view the documents tab in the
submission's workspace.
Please review the Investigator Responsibilities guidance
(https://kb.wisc.edu/hsirbs/page.php?id=18881) , which includes a description of IRB
requirements for submitting continuing review progress reports, personnel changes, changes of
protocol and reportable events.
If you have general questions, please contact the Health Sciences IRBs at 608-263-2362. For
questions related to this submission, contact the assigned staff reviewer.